Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1595917rdf:typepubmed:Citationlld:pubmed
pubmed-article:1595917lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:1595917lifeskim:mentionsumls-concept:C0006400lld:lifeskim
pubmed-article:1595917lifeskim:mentionsumls-concept:C0028094lld:lifeskim
pubmed-article:1595917lifeskim:mentionsumls-concept:C0600688lld:lifeskim
pubmed-article:1595917lifeskim:mentionsumls-concept:C0348016lld:lifeskim
pubmed-article:1595917lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:1595917pubmed:issue6lld:pubmed
pubmed-article:1595917pubmed:dateCreated1992-6-26lld:pubmed
pubmed-article:1595917pubmed:abstractTextWe examined nimodipine modification of bupivacaine toxicity in anesthetized male rats. Three minutes after pretreatment, group 1 (n = 11), group 3 (n = 10), and their respective control groups (n = 11 and n = 9) received intravenous bupivacaine LD50 (median lethal dose). After pretreatment, group 2 (n = 10), group 4 (n = 8), and their respective control groups (n = 10 and n = 8) received intravenous bupivacaine LD90 (90% lethal dose). Pretreatment was 200 micrograms/kg intravenous nimodipine in groups 1 and 2 and 500 micrograms/kg in groups 3 and 4. Control animals were pretreated with intravenous saline solution. Data were analyzed by chi 2-analysis and analysis of variance. Survival increased after 200 micrograms/kg nimodipine (P less than 0.05). In group 1, 9 (81%) of 11 survived compared with control animals (4 [36%] of 11). In group 2, 8 (80%) of 10 survived compared with control animals (2 [20%] of 10). Survival was not increased after 500-micrograms/kg nimodipine pretreatment. In group 3, 2 (22%) of 9 survived compared with control animals (4 [40%] of 10). In group 4, 4 (50%) of 8 survived compared with control animals (2 [25%] of 8). We conclude that nimodipine pretreatment with 200 micrograms/kg protects against fatal toxicity from LD50 and LD90 bupivacaine, but 500 micrograms/kg does not.lld:pubmed
pubmed-article:1595917pubmed:languageenglld:pubmed
pubmed-article:1595917pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1595917pubmed:citationSubsetAIMlld:pubmed
pubmed-article:1595917pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1595917pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1595917pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1595917pubmed:statusMEDLINElld:pubmed
pubmed-article:1595917pubmed:monthJunlld:pubmed
pubmed-article:1595917pubmed:issn0003-2999lld:pubmed
pubmed-article:1595917pubmed:authorpubmed-author:HornJ LJLlld:pubmed
pubmed-article:1595917pubmed:authorpubmed-author:KambamJ RJRlld:pubmed
pubmed-article:1595917pubmed:authorpubmed-author:HymanS ASAlld:pubmed
pubmed-article:1595917pubmed:authorpubmed-author:KinneyW WWWlld:pubmed
pubmed-article:1595917pubmed:authorpubmed-author:SkelleyC CCClld:pubmed
pubmed-article:1595917pubmed:issnTypePrintlld:pubmed
pubmed-article:1595917pubmed:volume74lld:pubmed
pubmed-article:1595917pubmed:ownerNLMlld:pubmed
pubmed-article:1595917pubmed:authorsCompleteYlld:pubmed
pubmed-article:1595917pubmed:pagination851-5lld:pubmed
pubmed-article:1595917pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:meshHeadingpubmed-meshheading:1595917-...lld:pubmed
pubmed-article:1595917pubmed:year1992lld:pubmed
pubmed-article:1595917pubmed:articleTitleNimodipine reduces the toxicity of intravenous bupivacaine in rats.lld:pubmed
pubmed-article:1595917pubmed:affiliationDepartment of Anesthesiology, Vanderbilt University, School of Medicine, Nashville, Tennessee 37232-2125.lld:pubmed
pubmed-article:1595917pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1595917pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:1595917pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed